# Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.

> **NCT06072612** · PHASE3 · RECRUITING · sponsor: **BriaCell Therapeutics Corporation** · enrollment: 404 (estimated)

## Conditions studied

- Breast Cancer
- Metastatic Breast Cancer
- Breast Neoplasm
- Breast Cancer Metastatic
- End Stage Cancer

## Interventions

- **BIOLOGICAL:** SV-BR-1-GM
- **DRUG:** Cyclophosphamide
- **DRUG:** Interferon infiltration of the inoculation site
- **DRUG:** Retifanlimab
- **DRUG:** Treatment of Physician's Choice

## Key facts

- **NCT ID:** NCT06072612
- **Lead sponsor:** BriaCell Therapeutics Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-12-05
- **Primary completion:** 2027-12
- **Final completion:** 2028-06
- **Target enrollment:** 404 (ESTIMATED)
- **Last updated:** 2026-04-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06072612

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06072612, "Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06072612. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*